secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2024-01-23T23:59:59+00:00
Accession:  0001493152-24-003465
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte launches VitaGraft Kidney test for transplant monitoring
-----------------------------------------------------------------

- VitaGraft Kidney, a blood-based dd-cfDNA test for kidney transplant rejection, is now broadly available upon request.
- Previously limited to Oncocyte's Early Access Program; official launch announced via LinkedIn on Jan 22, 2024.
- Test measures donor-derived cell-free DNA concentrations post-transplantation as indicator for organ damage or rejection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224003465/0001493152-24-003465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224003465/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-003465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer